Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients — Stella
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(14 sites)
China
Beijing Tsinghua Changgung Hospital, Beijing
People's Liberation Army General Hospital (1st and 6th Medical Centre), Beijing
West China Hospital, Sichuan University, Chengdu
Shandong Cancer Hospital, Jinan
Singapore
National University Hospital, Singapore
National Cancer Centre Singapore, Singapore
South Korea
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Taiwan
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City